参考文献:1.Warburg O (1956) On the origin of cancer cells. Science 123:309–314CrossRef PubMed 2.Dang CV, Semenza GL (1999) Oncogenic alterations of metabolism. Trends Biochem Sci 24:68–72CrossRef PubMed 3.Mueckler M (1994) Facilitative glucose transporters. Eur J Biochem 219:713–725CrossRef PubMed 4.Brown RS, Wahl RL (1993) Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 72:2979–2985CrossRef PubMed 5.Gillies RJ, Robey I, Gatenby RA (2008) Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49:24S–42SCrossRef PubMed 6.DeLaPaz RL, Patronas NJ, Brooks RA et al (1983) Positron emission tomographic study of suppression of gray-matter glucose utilization by brain tumors. AJNR Am J Neuroradiol 4:826–829PubMed 7.Rigo P, Paulus P, Kaschten BJ et al (1996) Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 23:1641–1674CrossRef PubMed 8.Luciani A, Olivier JC, Clement O et al (2004) Glucose-receptor MR imaging of tumors: study in mice with PEGylated paramagnetic niosomes. Radiology 231:135–142CrossRef PubMed 9.Zhang W, Chen Y, da Guo J et al (2011) The synthesis of a D-glucosamine contrast agent, Gd-DTPA-DG, and its application in cancer molecular imaging with MRI. Eur J Radiol 79:367–374 10.Canet E, Revel D, Sebbag L et al (1995) Noninvasive assessment of no-reflow phenomenon in a canine model of reperfused infarction by contrast-enhanced magnetic resonance imaging. Am Heart J 130:949–956CrossRef PubMed 11.Shan XH, Hu H, Xiong F et al (2012) Targeting Glut1-overexpressing MDA-MB-231 cells with 2-deoxy-D-g1ucose modified SPIOs. Eur J Radiol 81:95–99CrossRef PubMed 12.Molday RS (1984) US Patent 4452773 13.Xiong F, Zhu ZY, Xiong C et al (2012) Preparation, characterization of 2-deoxy-D-glucose functionalized dimercaptosuccinic acid-coated maghemite nanoparticles for targeting tumor cells. Pharm Res 29:1087–1097CrossRef PubMed 14.Gupta AK, Gupta M (2005) Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic nanoparticles. Biomaterials 26:1565–1573CrossRef PubMed 15.Zimmer C, Wright SC Jr, Engelhardt RT et al (1997) Tumor cell endocytosis imaging facilitates delineation of glioma ain interface. Exp Neurol 143:61–69CrossRef PubMed 16.Zimmer C, Weissleder R, Poss K et al (1995) MR imaging of phagocytosis in experimental gliomas. Radiology 197:533–538CrossRef PubMed 17.Moore A, Weissleder R, Bogdanov A Jr (1997) Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging 7:1140–1145CrossRef PubMed 18.Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE (2008) Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 5:487–495PubMedCentral CrossRef PubMed 19.Chouly C, Pouliquen D, Lucet I et al (1996) Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J Microencapsul 13:245–255CrossRef PubMed 20.Clavo AC, Brown RS, Wahl RL (1995) Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 36:1625–1632PubMed 21.Haberkorn U, Ziegler SI, Oberdorfer F et al (1994) FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 21:827–834CrossRef PubMed 22.Chen Y, Huang ZW, He L et al (2006) Synthesis and evaluation of technetium-99m-labeled diethyl netri amine pentaacetate-deoxyglucose complex ([99mTc]-DTPA-DG) as a potential imaging modality for tumors. Appl Radiat Isot 64:342–347CrossRef PubMed 23.Hatanaka M (1974) Transport of sugars in tumor cell membranes. Biochim Biophys Acta 1974(355):77–104 24.Airley R, Evans A, Mobasheri A, Hewitt SM (2010) Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: study using tissue microarrays. Ann Anat 192:133–138CrossRef PubMed 25.Shan X, Wang D, Chen J et al (2013) Necrosis degree displayed in computed tomography images correlated with hypoxia and angiogenesis in breast cancer. J Comput Assist Tomogr 37:22–28CrossRef PubMed 26.Petri-Fink A, Chastellain M, Juillerat-Jeanneret L et al (2005) Development of functionalized superparamagnetic iron oxide nanoparticles for interaction with human cancer cells. Biomaterials 26:2685–2694CrossRef PubMed 27.Gupta AK, Gupta M (2005) Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26:3995–4021CrossRef PubMed 28.Lewin M, Carlesso N, Tung CH et al (2000) Tat peptide derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 18:410–414CrossRef PubMed 29.Gupta AK, Naregalkar RR, Vaidya VD, Gupta M (2007) Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine (Lond) 2:23–39CrossRef
作者单位:Xiu Hong Shan (1) Peng Wang (1) Fei Xiong (3) Ning Gu (3) Hui Hu (1) Wei Qian (1) Hao Yue Lu (4) Yu Fan (2)
1. Department of Radiology, The Affiliated Renmin Hospital of Jiangsu University, Zhenjiang, 212002, China 3. State Key Laboratory of Bioelectronics, Jiangsu Key Laboratory of Biomaterials and devices, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210009, China 4. Medical college, Jiangsu University, Zhenjiang, 212013, China 2. Oncology Institute, The Affiliated Renmin Hospital of Jiangsu University, Zhenjiang, 212002, China
刊物主题:Imaging / Radiology;
出版者:Springer US
ISSN:1860-2002
文摘
Purpose This study aims to evaluate the effect of dimercaptosuccinic acid (DMSA)-coated superparamagnetic iron oxide (γ-Fe2O3@DMSA) bearing the 2-deoxy-d-glucose (2-DG) ligand on targeting tumors with high-glucose metabolism.